Interpace Biosciences, Inc 8-K/A, filed Jan 28, 2020

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K/A

(AmendmentNo. 1)

CURRENTREPORT

PURSUANTTO SECTION 13 OR 15(D) OF THE

SECURITIESEXCHANGE ACT OF 1934

Dateof Report (Date of earliest event reported): January 15, 2020

INTERPACEBiosciences, INC.

(Exactname of Registrant as specified in its charter)

MorrisCorporate Center 1, Building C

300Interpace Parkway,

Parsippany,NJ 07054

(Address, including zip code, of Principal Executive Offices)

(855)776-6419

Registrant’s telephone number, including area code:

NotApplicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securitiesregistered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

[  ] Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

ExplanatoryNote

Interpace Biosciences, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) with the Securities and Exchange Commission on January 17, 2020 announcing that the Company had re-appointed and re-elected Eric Lev and Robert Gorman and appointed and elected Edward Chan (together with Messrs. Lev and Gorman, the “New Directors”) to the board of directors of the Company (the “Board”) effective as of January 15, 2020. This Amendment to the Original Form 8-K is being filed solely to amend and supplement the Original Form 8-K to include the committees to which the New Directors were named on January 22, 2020 described below. Except as described above, the disclosures and exhibits included in the Original Form 8-K otherwise remain unchanged.

Item5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangementsof Certain Officers.

On January 22, 2020, the Company named Edward Chan and Robert Gorman to the Compensation & Management Development Committee of the Board. Director Joseph Keegan no longer serves on the Compensation & Management Development Committee.

On the same date, the Company named Edward Chan and Eric Lev to the Nominating and Corporate Governance Committee of the Board.

On the same date, the Company named Eric Lev as Chair to a newly created Compliance and Regulatory Committee and named Edward Chan and Robert Gorman as such Committee members.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 28, 2020